Back to all programs At Capacity — Waitlist Open

Primary Immune Deficiency

Up to $3,800 available in assistance for Private/Uninsured & Public

Join Waitlist for Primary Immune Deficiency (opens in a new tab)

Primary Immune Deficiency - Privately Insured

At Capacity — Waitlist Open
Join Waitlist for Primary Immune Deficiency - Privately Insured (opens in a new tab)

Privately insured programs are designed for individuals with Group, COBRA, Individual, or Marketplace insurance, or are uninsured.

Am I likely eligible?

This is a guide, not a decision. Checking your eligibility takes a few questions and gives you an answer.

What assistance is available?

$3,800 total assistance available, shared across all types below

Uninsured

  • Copay At Capacity
  • Medical Expenses At Capacity
  • Travel Expense up to $500

Private Insurance

  • Copay At Capacity
  • Medical Expenses At Capacity
  • Premium At Capacity
  • Travel Expense up to $500

Primary Immune (PI) Deficiency is a chronic disorder of the body’s immune system, which means people are more likely to become sick with infections. People with PI are more likely to also have autoimmune disorders.  There are over 400 identified types of immune deficiencies and often it takes 7 to 10 years for a person to be diagnosed.  It is estimated that 1 in 2,000 people are impacted in the U.S.

Primary Immune Deficiency - Publicly Insured

At Capacity — Waitlist Open
Join Waitlist for Primary Immune Deficiency - Publicly Insured (opens in a new tab)

Programs for those with public or federally sponsored insurance include all forms of Medicare, Medicaid, Tricare, or Veterans.

Am I likely eligible?

This is a guide, not a decision. Checking your eligibility takes a few questions and gives you an answer.

What assistance is available?

$3,800 total assistance available, shared across all types below

  • Copay At Capacity
  • Medical Expenses At Capacity
  • Premium At Capacity
  • Travel Expense up to $500

Primary Immune (PI) Deficiency is a chronic disorder of the body’s immune system, which means people are more likely to become sick with infections. People with PI are more likely to also have autoimmune disorders.  There are over 400 identified types of immune deficiencies and often it takes 7 to 10 years for a person to be diagnosed.  It is estimated that 1 in 2,000 people are impacted in the U.S.

Diagnosis codes

Your provider uses one of these codes when confirming your diagnosis. You do not need to know your code to apply.

  • D70.0 Congenital agranulocytosis
  • D71 Functional disorders of polymorphonuclear neutrophils
  • D72.0 Genetic anomalies of leukocytes
  • D76 Other specified diseases with participation of lymphoreticular and reticulohistiocytic tissue
  • D76.1 Hemophagocytic lymphohistiocytosis
  • D80 Immunodeficiency with predominantly antibody defects
  • D80.0 Hereditary hypogammaglobulinemia
  • D80.1 Nonfamilial hypogammaglobulinemia
  • D80.2 Selective deficiency of immunoglobulin A [IgA]
  • D80.3 Selective deficiency of immunoglobulin G [IgG] subclasses
  • D80.4 Selective deficiency of immunoglobulin M [IgM]
  • D80.5 Immunodeficiency with increased immunoglobulin M [IgM]
  • D80.6 Antibody deficiency with near-normal immunoglobulins or with hyperimmunoglobulinemia
  • D80.7 Transient hypogammaglobulinemia of infancy
  • D80.8 Other immunodeficiencies with predominantly antibody defects
  • D80.9 Immunodeficiency with predominantly antibody defects, unspecified
  • D81 Combined immunodeficiencies
  • D81.0 Severe combined immunodeficiency [SCID] with reticular dysgenesis
  • D81.1 Severe combined immunodeficiency [SCID] with low T- and B-cell numbers
  • D81.2 Severe combined immunodeficiency [SCID] with low or normal B-cell numbers
  • D81.3 Adenosine deaminase [ADA] deficiency
  • D81.30 Adenosine deaminase deficiency, unspecified
  • D81.31 Severe combined immunodeficiency due to adenosine deaminase deficiency
  • D81.32 Adenosine deaminase 2 deficiency
  • D81.39 Other adenosine deaminase deficiency
  • D81.4 Nezelof's syndrome
  • D81.5 Purine nucleoside phosphorylase [PNP] deficiency
  • D81.6 Major histocompatibility complex class I deficiency
  • D81.7 Major histocompatibility complex class II deficiency
  • D81.8 Other combined immunodeficiencies
  • D81.81 Biotin-dependent carboxylase deficiency
  • D81.810 Biotinidase deficiency
  • D81.818 Other biotin-dependent carboxylase deficiency
  • D81.819 Biotin-dependent carboxylase deficiency, unspecified
  • D81.82 Activated Phosphoinositide 3-kinase Delta Syndrome [APDS]
  • D81.89 Other combined immunodeficiencies
  • D81.9 Combined immunodeficiency, unspecified
  • D82 Immunodeficiency associated with other major defects
  • D82.0 Wiskott-Aldrich syndrome
  • D82.1 Di George's syndrome
  • D82.2 Immunodeficiency with short-limbed stature
  • D82.3 Immunodeficiency following hereditary defective response to Epstein-Barr virus
  • D82.4 Hyperimmunoglobulin E [IgE] syndrome
  • D82.8 Immunodeficiency associated with other specified major defects
  • D82.9 Immunodeficiency associated with major defect, unspecified
  • D83 Common variable immunodeficiency
  • D83.0 Common variable immunodeficiency with predominant abnormalities of B-cell numbers and function
  • D83.1 Common variable immunodeficiency with predominant immunoregulatory T-cell disorders
  • D83.2 Common variable immunodeficiency with autoantibodies to B- or T-cells
  • D83.8 Other common variable immunodeficiencies
  • D83.9 Common variable immunodeficiency, unspecified
  • D84 Other immunodeficiencies
  • D84.0 Lymphocyte function antigen-1 [LFA-1] defect
  • D84.8 Other specified immunodeficiencies
  • D84.81 Immunodeficiency due to conditions classified elsewhere
  • D84.82 Immunodeficiency due to drugs and external causes
  • D84.821 Immunodeficiency due to drugs
  • D84.822 Immunodeficiency due to external causes
  • D84.89 Other immunodeficiencies
  • D84.9 Immunodeficiency, unspecified
  • D89 Other disorders involving the immune mechanism, not elsewhere classified
  • D89.0 Polyclonal hypergammaglobulinemia
  • D89.1 Cryoglobulinemia
  • D89.2 Hypergammaglobulinemia, unspecified
  • D89.3 Immune reconstitution syndrome
  • D89.4 Mast cell activation syndrome and related disorders
  • D89.40 Mast cell activation, unspecified
  • D89.41 Monoclonal mast cell activation syndrome
  • D89.42 Idiopathic mast cell activation syndrome
  • D89.43 Secondary mast cell activation
  • D89.49 Other mast cell activation disorder
  • D89.8 Other specified disorders involving the immune mechanism, not elsewhere classified
  • D89.81 Graft-versus-host disease
  • D89.810 Acute graft-versus-host disease
  • D89.811 Chronic graft-versus-host disease
  • D89.812 Acute on chronic graft-versus-host disease
  • D89.813 Graft-versus-host disease, unspecified
  • D89.82 Autoimmune lymphoproliferative syndrome [ALPS]
  • D89.89 Other specified disorders involving the immune mechanism, not elsewhere classified
  • D89.9 Disorder involving the immune mechanism, unspecified
  • E70.330 Chediak-Higashi syndrome
  • G11.3 Cerebellar ataxia with defective DNA repair

Covered medications

72 medications are covered by this program. Assistance is not limited to medication costs.

  • Abatacept
  • Actimmune
  • Alyglo
  • Asceniv
  • Axatilimab-csfr
  • Belumosudil Mesylate
  • Bivigam
  • Cromolyn Sodium
  • Cutaquig
  • Cuvitru
  • Elapegademase-lvlr
  • Emapalumab-lzsg
  • Flebogamma DIF
  • Gamifant
  • Gammagard
  • Gammagard ERC
  • Gammagard S/D Less IgA
  • Gammaked
  • Gammaplex
  • Gamunex-C
  • Gastrocrom
  • Hizentra
  • Hyqvia
  • Ibrutinib
  • Imbruvica
  • Immune Globulin (Human)
  • Immune Globulin (Human)-dira
  • Immune Globulin (Human)-hipp
  • Immune Globulin (Human)-ifas
  • Immune Globulin (Human)-klhw
  • Immune Globulin (Human)-kthm
  • Immune Globulin (Human)-slra
  • Immune Globulin (Human)-stwk
  • Immune Globulin-Hyaluronidase
  • Inebilizumab-cdon
  • Interferon Gamma-1B
  • Jakafi
  • Jakafi XR
  • Joenja
  • Leniolisib Phosphate
  • Mavorixafor
  • Niktimvo
  • Octagam
  • Orencia
  • Orencia ClickJect
  • Panzyga
  • Privigen
  • Qivigy
  • Remestemcel-L-rknd
  • Revcovi
  • Rezurock
  • Ruxolitinib Phosphate
  • Ruxolitinib Phosphate ER
  • Ryoncil <12.5kg
  • Ryoncil 100kg to <112.5kg
  • Ryoncil 112.5kg to <125kg
  • Ryoncil 12.5kg to <25kg
  • Ryoncil 125kg to <137.5kg
  • Ryoncil 137.5kg to <150kg
  • Ryoncil 25kg to <37.5kg
  • Ryoncil 37.5kg to <50kg
  • Ryoncil 50kg to <62.5kg
  • Ryoncil 62.5kg to <75kg
  • Ryoncil 75kg to <87.5kg
  • Ryoncil 87.5kg to <100kg
  • Tocilizumab-aazg
  • Tyenne
  • Uplizna
  • Xembify
  • Xolremdi
  • Yimmugo
  • raNITIdine HCl

Resources

These organizations offer information and support for this condition. They are independent of Accessia Health, and may not currently have assistance available for this program.

Ready to find out if you qualify?

Checking your eligibility takes a few questions and gives you an answer. If this program is at capacity you can join the waitlist and we will contact you when it reopens.

Join Waitlist (opens in a new tab)